	RATING score sheet	Points	Applicable/ relevant	Answer yes			
Questions for the Introduction							
	The study aim formulated by research questions						
1	Does the study have a concise and precise study aim, defined with a	10					
	restricted number of interconnected questions?			✓			
	The motivation for the research questions						
2	Has relevant up to date literature been included to support the need	5					
	for the current study?			✓			
3	Does the study address an existing knowledge gap?	10		✓			
Qu	estions for Materials and Methods						
4	Is the global study design adequate for answering the posed research	10		V			
	questions?						
5	Is the global study design described in sufficient detail for others to	5					
	interpret and reproduce the results?			✓			
	Patient cohort						
6	Are the inclusion and exclusion criteria of the patient cohort	1					
	described?			Ш			
7	Is the clinical patient information of the cohort presented, including	1					
	disease type, site(s) and clinical staging?			Ш			
8	Is the included number of patients stated, explained and justified?	1	J				
9	Has there been consideration of the need for ethical and/or legal	5					
	approval for the study and if needed, is there a statement about this?			7			
	Imaging procedures			V			
10	Have the scanning parameters been reported in sufficient detail	1					
	(image modalities, equipment model, slice thickness, voxel size, patient		J	$\overline{\checkmark}$			
	position (e.g. head first, supine, etc.) etc.)?		_				
11	Has the applied immobilisation equipment been described, (e.g.	1					
	vendor and type, standard settings, etc.) where relevant?						
	Treatment machine and settings						
12	Have the treatment machine and relevant parameters been described	1					
	with sufficient detail (model, beam energy, MLC, etc.)?		✓	✓			
13	Have the monitor unit reference conditions been defined, where	1					
	relevant?			Ш			
	Definition of targets and OARs						
14	Has GTV definition been described in sufficient detail, with references	1					
	if possible?			Ш			
15	Has CTV definition been described in sufficient detail, with references	1	7				
	if possible?		<u> </u>	\			
16	Has the establishment of PTVs (or alternatively robustness settings)	1	7	~			
	been described in sufficient detail?		<u> </u>				
17	Have PTV sizes in the patient cohort been described?	1	✓	✓			
18	Have OAR definitions been described in sufficient detail, with	1					
	references if possible?						
19	Have PRV margins been described in sufficient detail, with references if	1					
	available?		Ш	Ш			

Treatment planning system and dose calculation Have all applied dose calculation algorithms been described in 20 1 **√** 1 sufficient detail? For any commercial software used, have the manufacturer, algorithms 21 1 1 1 and specific versions been stated? Have all relevant user parameters and settings in the TPS been 22 1 1 1 reported, e.g. beams, dose grid, control point spacing? 23 Have all volumes been evaluated with the same 1 1 1 software/methodology? Planning aims and optimisation Are clear planning aims defined, including imposed hard constraints 5 ✓ and planning objectives (with or without soft constraints)? 25 Has the ranking of planning objectives (priorities) been described? 5 Is the dose prescription clearly defined? 10 Is there a narrative description of the applied optimisation process, 5 1 including the handling of all objectives with their ranking? 28 If manual intervention during or after optimisation is allowed, has this 1 been described? Bias mitigation Have enough study details been provided such that bias issues could 5 ✓ be noted? Has bias been sufficiently mitigated to reliably answer the posed 10 **✓** research question? Plan acceptability – minor and major protocol deviations Was the procedure for assessment of plan acceptability well-31 1 **✓ J** described? 32 Was the procedure for assessment of minor and major protocol 1 **✓** deviations well described? Plan (re-)normalisation for plan comparisons 33 Has plan (re-)normalisation been described sufficiently? 1 Dose-volume parameters for plan evaluation and comparison 34 Have sufficiently comprehensive dose-volume parameters been used 5 **✓** for plan evaluations and comparisons? Population-mean DVHs 35 Has the algorithm for creating population-mean/median DVHs been 1 reported? Have the definitions of confidence intervals been included? 1 36 Plan evaluations by clinicians Have clinicians scored plans to assess quality? 1 **✓** ✓ 37 **✓ ✓** 38 Were plan comparisons by clinicians blinded? 1 Predicted tumour control probability and normal tissue Have any applied TCP models been described and referenced? 1 Have any applied NTCP models been described and referenced? 1 Plan deliverability and complexity Have methods used to assess plan deliverability and complexity been 1 described in sufficient detail?

	Composite plan quality metrics			
42	Is there a sufficient basis (e.g. in the literature) for any selected	1		
	composite plan quality metrics?			
43	Is there an adequate description of the calculation of the composite	1		
	plan quality metrics?			
	Planning and delivery times			
44	Has measurement of planning times been described in sufficient	1	V	$\overline{\checkmark}$
	detail?			
45	Has the establishment of delivery times been described in sufficient	1	V	V
	detail?			
	Statistical analysis			
46	Have proper statistical methods been used and described in sufficient	5		7
	detail?			_
47	In case of multiple testing for research questions, has this been	1		
	handled appropriately?			
-	estions for Results			1
48	Does the provided data contribute to (at least partly) answering all	10		
	aspects of the research questions, e.g. plan acceptability, dosimetric			~
	quality, deliverability and planning and delivery times?			_
	Dose distribution reporting			
49	Are complete summaries of the dose distributions in the patient cohort	5		
	provided (low doses, high doses, OARs, PTV, patient, etc.)?			_
50	Are tables and figures optimised to clearly present the results	1	V	V
	obtained?			
51	Have the answers to the research questions been illustrated for an	1		
	example patient by providing dose distributions, DVHs, etc.?		\checkmark	✓
	Plan acceptability reporting – minor and major protocol deviations			
52	In case of treatment technique or planning technique comparisons,	1	~	V
- 2	was plan acceptability reported separately for each technique?	4	Ŭ	Ľ
53	Has plan acceptability been reported in sufficient detail: how many	1		
	plans were acceptable, how many were not and for what reasons (e.g.		✓	✓
	violation of hard constraints, violation of soft constraints, other			
54	reasons)? Was there adequate reporting of minor and major protocol deviations?	1		
54	Deliverability and complexity reporting	1	✓	
	Has the deliverability of the plans been adequately reported?	1	$\overline{}$	
55 56	Have plan deliverability and complexity been investigated in sufficient		Ш	
30	detail in relation to the posed research questions?	1		
	Planning and delivery times reporting			
57	Have planning and delivery times been adequately evaluated and	1		
37	reported?	1	✓	✓
	Patient-specific analyses reporting			
58	Is there sufficient description of inter-patient variations in the results	1		
50	presented?	_	✓	✓
59	Have outlier patients been reported and has any exclusion from	1		
	population analyses been sufficiently motivated and explained?	_		
	, , , , , , , , , , , , , , , , , , ,			

	Statistical reporting						
60	Are the p-values reported appropriately?	1	V	/			
61	Are there confidence intervals for the appropriate parameters?	1					
Questions for discussions							
62	Is there an overall interpretation of the data presented in the Results	10					
	section as to how the posed research questions are answered?						
	Comparison with literature						
63	Has the study been sufficiently discussed in the context of existing	5					
	literature?			<u> </u>			
	Clinical and statistical significance						
64	Does the discussion focus on statistically significant results?	1					
65	Is the potential clinical significance of the results clearly discussed	5		V			
	(assuming practical application would be feasible)?			<u> </u>			
	Clinical applicability of the study						
66	Is future the clinical applicability sufficiently discussed?	1					
	Study limitations						
67	Has the impact of the study limitations on the provided answers to the	10		-			
	research questions been sufficiently discussed?			<u> </u>			
	Future work						
68	Has the potential future work arising from the study been discussed?	1	J	V			
Que	stions for conclusions						
69	Do the presented conclusions represent answers to the posed research	5		7			
	questions?						
70	Are the conclusions fully supported by the results?	5		✓			
71	Are the conclusions a fair summary of all results?	5		✓			
Que	stions for supplementary						
	Supplementary materials						
72	Is the information presented in the supplementary material of	1		/			
	sufficient relevance?						
73	Is the presentation of the included information of sufficient quality,	1	✓	4			
	including readability?	_					
74	Has sufficient underlying data been made available or a willingness to	5		7			
	share data been indicated, within local data sharing restrictions?						
RAT	ING remarks						
75	Is the RATING score added to the manuscript?	5		✓			
76	Is the accompanying question table added to the cover letter or the	1	√	J			
	supplementary material?						
			0.657				
	RATING score		96%				
	RATING fraction	185	of	193			